Acupuncture Treatment on Cerebral Blood Flow

High Blood Pressure Clinical Trial

— Amp-HTN  

Official title:

Effects of Anti-Hypertensive Acupuncture Treatment on Cerebral Blood Flow Responses to Exercise in Hypertensive Humans

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04346511
• Other study ID #: 11943
• Status: Withdrawn
• Phase: Phase 2
• Start date: May 9, 2020
• Est. completion date: December 5, 2022

Study information

• Verified date: November 2023
• Source: University of Oklahoma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Cerebrovascular diseases (CVD) and neurodegenerative diseases (NDD) are both leading causes of death in the United States. Epidemiological data have shown that increased prevalence of hypertension is related to these outcomes. However, despite the strong association of poor brain health outcomes in patients with hypertension (HTN), the understanding of cerebral blood flow (CBF) regulation and treatment options for HTN remain limited. Acupuncture treatment (AT), which is considered a promising complementary and integrative modality, has been known to reduce blood pressure and improve endothelial function in HTN. However, very few studies have investigated AT's effect on cerebrovascular function and the possible neuroprotective properties directly via regulating HTN. Exercise is used as a stimulus that increases the brain's metabolism and requires cerebrovascular responses (vasodilation) to meet the new metabolism. Therefore, the specific aim of this study is to test the hypothesis that an antihypertensive acupuncture treatment can acutely improve cerebrovascular responses in hypertensive humans during moderate exercise.

Description:

After IRB approval, experiments will take place in the Human Circulation Research Laboratory in the Department of Health and Exercise on the OU Norman campus. All subjects will complete a total of 3 visits. The first is a screening visit to provide informed consent and to ensure the potential participant meets all inclusion criteria and no exclusion criteria. Once enrolled, participants will complete two experimental trials (Placebo (PL, Sham Acupuncture) or Real Acupuncture (RA), randomized) in a single-blinded crossover design. PL or RA treatment will precede testing by ~25min before to maximize acute responses. Test begins with 5 min of quiet rest where baseline measurements are taken, followed by 5 min of exercise. After exercise, subjects will be given 5 min of quiet rest. Visit 1 (Screening day): ~1.5 hours. The screening visit will include informed consent, health history, physical activity questionnaires and blood sample. If qualified, the subject will be enrolled in the study and they will complete a maximal oxygen uptake (VO2max) cycle ergometer test to determine fitness. Visit 2 & 3 (Study day): ~1.5 hours. Instrumentation: Subjects will be equipped with ECG for heart rate (HR), photoplethysmography for blood pressure, pulse oximeter, mouthpiece for end-tidal CO2 (PETCO2) and oxygen uptake (VO2), near-infrared spectroscopy (NIRS) for active muscle oxygenation and Transcranial Doppler (TCD) for CBF. Real Acupuncture (RA): Subjects will receive ~20 minutes of RA treatment prior to exercise. Placebo (PL): Specially designed Sham Acupuncture needles will be used in the same acupoints, for the same duration as RA. All subjects will complete a total of 3 visits separated by a minimum of 48 hours. Each study visit will take ~1.5 hours. The investigators anticipate ~ 6 hours or less of total involvement of the participants' time. This study is a single-blind crossover design. Participants will be blinded in two trials. Practitioners and operators will not be allowed to communicate with the participants concerning the type of acupuncture devices. Outcome assessors and statisticians may not be blinded to treatment allocation. The key dependent variable of interest is change (delta) in cerebrovascular conductance index (CVCi = CBF/blood pressure) from rest to exercise (delta CVCi = CVCiExercise - CVCiRest). Delta CVCi is the most common assessment of vasodilation in humans as it normalizes differences in blood flow to differences in blood pressure. CVCi calculates how much blood flow is observed for a given pressure. A change in CVCi (delta CVCi) has a predictable relationship where + delta CVCi indicates vasodilation (more flow for a given pressure) and - delta CVCi indicates vasoconstriction (less flow for a given pressure). Data will be analyzed using a general linear model approach (similar to ANOVA). Based on pilot data, a total sample size of 40 (20 CON and 20 HTN) will provide a power of 0.9. A minimum of 60 participants will be to recruited to ensure statistical power is achieved.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 5, 2022
• Est. primary completion date: December 5, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

Subjects will include healthy controls (CON) and Hypertension (HTN) patients between 18-65 years of age. Female participants if premenopausal will be studied in the early follicular phase of their cycle to minimize vascular effects of circulating hormones. HTN: 1) Stage 1 hypertensive, Systolic BP (SBP) = 130 mmHg and/or Diastolic BP (DBP) > 80 mmHg, and/or diagnosis of HTN, with BMI and physical activity levels ˜ CON

1. If they are on anti-hypertensive medication, the dose, type, and frequency of use will be recorded.

2. HTN with an SBP > 139 mmHg must have a medical doctor's permission to participate CON: will be age, BMI, menstrual status for females, and physical activity matched to HTN.

They must be:

1. Normotensive

2. Free of cardiovascular comorbidities.

Exclusion Criteria:

1. Diabetes

2. Coronary artery disease

3. Stroke

4. Heart attack

5. Sleep apnea

6. Tobacco use

7. Asthma

8. Pregnancy

9. Currently receiving antihypertensive acupuncture treatment

10. conditions where acupuncture might not be safe, such as metal allergy or needle-phobia. If a subject experiences severe acupuncture-associated response, it will be subject to early termination of the study.

Related Conditions & MeSH terms

• High Blood Pressure
• Hypertension

Intervention

Other:
• Acupuncture
Patients will have six, 0.25*40mm sterilized stainless steel acupuncture needles (Dongbang Acupuncture, Inc., Seoul, South Korea) inserted into six acupoints (sites ST36, LV3, KI2, bilaterally) on their lower legs. After insertion, the needles will be stimulated at 2-4Hz, 10s at each point (1min total), immediately after insertion, 5min, 10min, 15min and just before removal.

Locations

Country	Name	City	State
United States	Department of Health and Exercise Science	Norman	Oklahoma

Sponsors (1)

Lead Sponsor	Collaborator
University of Oklahoma

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cerebrovascular Conductance Index	Middle Cerebral Artery Blood Velocity relative to Mean Arterial Pressure (MCABV/MAP)	5 min of moderate exercise
Primary	Middle cerebral artery blood velocity	Velocity of blood through the middle cerebral arteries	5 min of moderate exercise
Primary	Mean Arterial Pressure	Integral of blood pressure waveform	5 min of moderate exercise
Secondary	Heart Rate Variability	measure of the variation in time between each heartbeat	before and after acupuncture
Secondary	End-tidal CO2	Partial pressure carbon dioxide (CO2) at the end of an exhaled breath	5 min of moderate exercise
Secondary	Oxygen Uptake	Volume of oxygen consumed by the body per minute	5 min of moderate exercise
Secondary	peripheral capillary oxygen saturation	estimate of the amount of oxygen in the blood	5 min of moderate exercise
Secondary	Tissue saturation index	estimate of the amount of oxygen in muscle	5 min of moderate exercise
Secondary	blood glucose levels	venous blood content	prior to enrollment
Secondary	blood triglyceride levels	venous blood content	prior to enrollment
Secondary	blood high density lipoprotein levels	venous blood content	prior to enrollment
Secondary	blood low density lipoprotein levels	venous blood content	prior to enrolment